SHR 1314Alternative Names: SHR-1314
Latest Information Update: 28 Oct 2016
Price : $50
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin-17 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
- Preclinical Autoimmune disorders
Most Recent Events
- 01 Aug 2016 Phase-I clinical trials in Psoriasis (In volunteers) in Australia (SC) (NCT02934412)
- 01 Jul 2016 Jiangsu Hengrui Medicine plans a phase I trial for Autoimmune diseases in China